Nuvig Therapeutics, Inc.
1775 Woodside Rd., Suite 201
About Nuvig Therapeutics, Inc.
Nuvig Therapeutics, Inc., headquartered in Redwood City, CA is an IND-enabling stage development company focused on fundamentally transforming treatments for inﬂammatory and autoimmune diseases. Our Development Candidate NVG-2089 is a novel, recombinant human IgG1 Fc modulator that binds anti-inflammatory receptors, upregulates an immune checkpoint and expands T reg cells for the treatment of autoimmune diseases. Pipelines efforts are focused on engineering full-length therapeutic antibodies with our technology to maximize their ability to control aggressive autoimmune diseases. The company was founded in 2021 by industry veterans who closed a $47 million Series A financing, led by Novo Holdings A/S and Platanus, joined by Bristol Myers Squibb, Digitalis Ventures, and Mission BioCapital.
At Nuvig, we believe that a empathic, diverse, collaborative, accountable and pragmatic culture is key to our success. We are seeking individuals seeking to make a real impact to a dynamic, fast-paced and early stage company to fundamentally improve the lives of patients living with autoimmune diseases.
3 articles about Nuvig Therapeutics, Inc.
Nuvig Therapeutics Appoints Julie Smith Chief Executive Officer
Nuvig Therapeutics, Inc., a biopharma company developing proprietary recombinant human therapeutics for patients with autoimmune diseases, announced the appointment of Julie Anne Smith as Chief Executive Officer and member of the Board of Directors.
This week's Movers & Shakers include Arvinas, Inspire and Cambridge Isotope Laboratories all announcing new VP roles, and several others tap new C-suite executives.
Nuvig Therapeutics Expands Leadership Team with the Appointment of Dr. Joanne Quan as Chief Medical Officer
Nuvig Therapeutics, Inc. announced today the appointment of Joanne Quan, M.D., as Chief Medical Officer.